NASDAQ
Intra-Cellular Therapies, Inc. (ITCI) has a price/sales ratio of 12.65x as of Friday, May 22, 2026. This represents a 72.81% decrease compared to its 12-month average of 46.53x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.